Connect with us

Cancer

Juncker Plan supports €40 million loan to finance research of #CancerTreatment

SHARE:

Published

8 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Juncker Plan's European Fund for Strategic Investments (EFSI) has provided its backing to a European Investment Bank (EIB) loan worth €40 million to biotechnology company Nanobiotix. The loan will help finance research and development by Nanobiotix of innovative cancer treatments.

Commenting on the agreement, Commissioner Vytenis Andriukaitis said: "Cancer is the second-highest cause of death in the EU and with Europe's ageing population, fighting cancer will undoubtedly remain a priority in the years to come.  We need to have innovative and dedicated research to always be in search of new treatments. Nanoparticle-based cancer treatment research funding is one example of how serious we are in fighting cancer, with the significant support from the EIB to finance research and innovation."

These latest loan agreements come following the confirmation that the Juncker Plan's European Fund for Strategic Investments (EFSI) has mobilized €335 billion in additional investment across the EU since July 2015, exceeding the initial target of mobilizing €315 billion of investment. Factsheets on the results of the Juncker Plan are available here. A press release is available here.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending